Sergei Timofeevski

Sergei Timofeevski

UNVERIFIED PROFILE

Are you Sergei Timofeevski?   Register this Author

Register author
Sergei Timofeevski

Sergei Timofeevski

Publications by authors named "Sergei Timofeevski"

Are you Sergei Timofeevski?   Register this Author

21Publications

1042Reads

15Profile Views

Reviving B-Factors: Activating ALK Mutations Increase Protein Dynamics of the Unphosphorylated Kinase.

ACS Med Chem Lett 2018 Sep 24;9(9):872-877. Epub 2018 Aug 24.

Pfizer Worldwide Research and Development, La Jolla Oncology, 10770 Science Center Drive, San Diego, California 92121, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsmedchemlett.8b00348DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142052PMC
September 2018

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

N Engl J Med 2016 Jan 23;374(1):54-61. Epub 2015 Dec 23.

Massachusetts General Hospital Cancer Center (A.T.S., L.F., J.F.G., L.D., R.L.F., K.R.S., J.L., G.G., J.A.E.) and the Department of Pathology (A.J.I., L.L., G.G.), Massachusetts General Hospital, Boston, and the Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge (I.L., G.G.) - all in Massachusetts; Pfizer Worldwide Research and Development, La Jolla, CA (S.B., A.B., B.J.B., Y.-L.D., W.L., L.P.J., T.S., S.T., M.M., T.W.J.); and the Japanese Foundation for Cancer Research, Tokyo (R.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1508887DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773904PMC
January 2016

Engineering of an isolated p110α subunit of PI3Kα permits crystallization and provides a platform for structure-based drug design.

Protein Sci 2014 Oct 7;23(10):1332-40. Epub 2014 Aug 7.

Oncology Structural Biology, Worldwide Research and Development, Pfizer Inc., San Diego, California, 92121.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/pro.2517
Publisher Site
http://dx.doi.org/10.1002/pro.2517DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286995PMC
October 2014

Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.

Biochemistry 2009 Jun;48(23):5339-49

Pfizer Global Research and Development, La Jolla, Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/bi900438wDOI Listing
June 2009

Identification of small-molecule inhibitors of the JIP-JNK interaction.

Biochem J 2009 May 13;420(2):283-94. Epub 2009 May 13.

Department of Target Biology, Pfizer Research Technology Center, Cambridge, MA 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1042/BJ20081899DOI Listing
May 2009

Pharmacological characterization of a small molecule inhibitor of c-Jun kinase.

Am J Physiol Endocrinol Metab 2008 Nov 26;295(5):E1142-51. Epub 2008 Aug 26.

Diabetes Biology Department, Pfizer Incorporated, San Diego, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1152/ajpendo.90298.2008DOI Listing
November 2008

Isoform-selective interaction of cyclooxygenase-2 with indomethacin amides studied by real-time fluorescence, inhibition kinetics, and site-directed mutagenesis.

Biochemistry 2002 Jul;41(30):9654-62

Department of Biochemistry, Center in Molecular Toxicology, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/bi0203637DOI Listing
July 2002